7096 Stock Overview
Engages in the stem cell banking business in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
StemCell Institute Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,243.00 |
| 52 Week High | JP¥2,358.00 |
| 52 Week Low | JP¥1,213.00 |
| Beta | 0.62 |
| 1 Month Change | -23.51% |
| 3 Month Change | -24.89% |
| 1 Year Change | -38.77% |
| 3 Year Change | -45.96% |
| 5 Year Change | n/a |
| Change since IPO | -39.81% |
Recent News & Updates
Recent updates
StemCell Institute Inc. (TSE:7096) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Dec 06
StemCell Institute's (TSE:7096) Returns On Capital Not Reflecting Well On The Business
Nov 14StemCell Institute Inc. (TSE:7096) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing
Aug 05Shareholder Returns
| 7096 | JP Healthcare | JP Market | |
|---|---|---|---|
| 7D | -2.9% | -2.0% | -1.5% |
| 1Y | -38.8% | -9.4% | 13.7% |
Return vs Industry: 7096 underperformed the JP Healthcare industry which returned -9.4% over the past year.
Return vs Market: 7096 underperformed the JP Market which returned 13.7% over the past year.
Price Volatility
| 7096 volatility | |
|---|---|
| 7096 Average Weekly Movement | 6.5% |
| Healthcare Industry Average Movement | 3.3% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 7096's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 7096's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 98 | Takafumi Shimizu | www.stemcell.co.jp |
StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan.
StemCell Institute Inc. Fundamentals Summary
| 7096 fundamental statistics | |
|---|---|
| Market cap | JP¥12.74b |
| Earnings (TTM) | JP¥422.00m |
| Revenue (TTM) | JP¥2.64b |
30.2x
P/E Ratio4.8x
P/S RatioIs 7096 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7096 income statement (TTM) | |
|---|---|
| Revenue | JP¥2.64b |
| Cost of Revenue | JP¥965.00m |
| Gross Profit | JP¥1.68b |
| Other Expenses | JP¥1.25b |
| Earnings | JP¥422.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 41.18 |
| Gross Margin | 63.46% |
| Net Profit Margin | 15.98% |
| Debt/Equity Ratio | 0% |
How did 7096 perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 03:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
StemCell Institute Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Masatoshi Nagata | Ichiyoshi Research Institute Inc. |
| null null | Storm Research Limited |